Navigation Links
Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
Date:10/6/2008

Vice President and Chief Medical Officer at Ironwood.

"These novel findings provide valuable insight into the possible role of cGMP in alleviating intestinal pain and may explain the reduction in intestinal pain observed in patients with IBS-C treated with linaclotide in our Phase 2b studies," said Mark Currie, Ph.D., Senior Vice President, R&D and Chief Scientific Officer at Ironwood.

About Linaclotide

Linaclotide is a first-in-class compound currently being evaluated for the treatment of IBS-C, chronic constipation (CC), and other gastrointestinal disorders. Linaclotide was designed to exert its effect on the intestine with minimal systemic exposure. Linaclotide is an agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine. Linaclotide demonstrated proof of concept in a comprehensive Phase 2b program, comprised of two clinical studies in over 700 patients with either IBS-C or CC. In patients with IBS-C, linaclotide reduced abdominal pain and relieved constipation-the hallmarks of the condition-throughout the 12-week treatment period. In patients with CC, linaclotide reduced constipation throughout the 4-week study period. Linaclotide was well tolerated at all doses in both Phase 2b studies, with the most common adverse event being diarrhea. A United States patent covering linaclotide composition of matter expires in 2025. In September 2007, Ironwood and Forest Laboratories entered into a 50/50 collaboration to co-develop and co-promote linaclotide in the United States. Ironwood retains exclusive rights to linaclotide outside of North America.

About Irritable Bowel Syndrome (IBS)

One out of six adults in developed countries suffers from IBS, a chronic condition marked by abdominal pain and disturbed bowel function. IBS accounts for 12% of adult visits to primary care physicians and is the most common disorder diagnosed by gastroenterologists. Healthcare costs associated with IBS exceed $25 billion ann
'/>"/>

SOURCE Ironwood Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
2. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
3. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
4. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
5. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. ... from a pre-clinical study published in the ... ( www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ibrutinib (IMBRUVICA ... (a checkpoint inhibitor), suppression of tumor growth was ... when treating certain hematologic cancers and solid tumors ...
(Date:2/27/2015)... , Feb. 27, 2015  Following a ... Committee that moved H.R. 284, the Medicare DMEPOS ... American Association for Homecare (AAHomecare) released a statement ... action to pass the legislation. "Today,s ... the House Ways and Means Committee is a ...
(Date:2/27/2015)... , Feb. 27, 2015 Securities lawyers ... board of Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP ... per share. Concerned SLXP investors are encouraged to contact ... The investigation focuses upon the shareholder value ... Salix shareholders would receive only $158.00 per share in ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2
... In 2009, more than 30 million people delayed seeking ... needed care due to the rising costs of healthcare in ... and cannot afford their prescriptions, medical treatment or even a ... dietary supplement brand with more than 10 years in the ...
... Jan. 24, 2011 NxStage Medical, Inc. (Nasdaq: ... products, today announced the addition of Nancy J. Ham ... of Jonathan T. Silverstein. Mr. Silverstein, General ... the Company,s 2008 financing, in which OrbiMed was the ...
Cached Medicine Technology:Codeco® Nutrilife Brings Hope to Hispanics Through Alternative Medicine 2NxStage® Appoints Nancy J. Ham to Its Board of Directors and Announces Resignation of Board Member Jonathan T. Silverstein 2
(Date:2/28/2015)... 28, 2015 The MCA Youth Empowerment ... into one platform and gears towards the goal for ... series of group talks in smaller groups will be ... Education, Personal Development, Leadership, Entrepreneurship, Healthcare, Social and Volunteerism, ... of Malaysian youths. , Young adults aged ...
(Date:2/28/2015)... Heart diseases are on the rise ... urban adult population and 5 percent of rural adult ... 20-30 percent of them require specialized investigation and treatment ... vascular diseases (CVD). , A division of Indian Business ... report titled “Indian Coronary Stent Market Forecast to 2019”. ...
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 people to ... thinking. “The #1 block was lack of time ... Haman, who created the Thinkubator Innovation Studio in Chicago. ... they did not have enough time for innovative thinking ... innovation. , Solutionman’s monthly “Accelerating Innovation Training” workshops address ...
(Date:2/28/2015)... February 28, 2015 The Heart Fit ... a distributor of the machine. The Heart Fit Clinic ... license, like a franchise model. The goal is to ... reverse heart disease. To buy External Counterpulsation ... can help individuals through this process and achieve the ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 March—also ... good time to remind ourselves and others that ... say Atlantic NeuroSurgical Specialists (ANS). , Concussions are ... account for 75% of TBIs. There are 1.6-3.8 ... may sound benign, but it is a brain ...
Breaking Medicine News(10 mins):Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3
... 5, 2011) Autism Speaks, the world,s largest autism ... leader in educating parents and professionals about the early ... University,s Autism Institute today announced the launch of a ... Video Glossary , giving parents an important new tool ...
... States, the cost paid for statins (drugs to lower ... have private insurance is approximately 400 percent higher than ... Kingdom (U.K.). These findings, from the Boston University School ... the first results of a comprehensive comparison of prescription ...
... Jan. 5 (HealthDay News) -- Man,s beloved four-legged friends not only ... understand and anticipate the intentions of their people, researchers are reporting. ... who had direct eye contact with a person were more likely ... than if the person didn,t make direct eye contact with them. ...
... More than half of U.S. jails didn,t receive any vaccine ... flu, a new study says. Jail and prison inmates ... steady stream of new arrivals can introduce new types of ... for diseases to spread, researchers from the U.S. Centers for ...
... , THURSDAY, Jan. 5 (HealthDay News) -- Giving antibiotics ... reduces infection rates in newborns, according to a new study. ... common in high-income nations and should also be used in ... study author Dr. Karen Edmond, of the London School of ...
... the Twin Cities would create both opportunities and potential risks ... would pass through, according to a health impact assessment (HIA) ... coalition of 90 congregations of various faiths in the Minneapolis, ... possible through a grant by the Health Impact Project, which ...
Cached Medicine News:Health News:Autism Speaks, FSU and First Signs launch Autism Video Glossary treatment section 2Health News:Study finds statin costs 400 percent higher in US compared to UK 2Health News:Like Babies, Dogs Pick Up on People's Intent 2Health News:Like Babies, Dogs Pick Up on People's Intent 3Health News:Many Jails Got No Flu Shots During H1N1 Outbreak: CDC 2Health News:Antibiotics in Pregnancy May Shield Newborns From Strep B 2Health News:Twin Cities light rail project presents both opportunities and risks for health, according to report 2Health News:Twin Cities light rail project presents both opportunities and risks for health, according to report 3
... When MAGNEVIST (gadopentetate dimeglumine) injection was introduced ... concept of contrast-enhanced magnetic resonance imaging (MRI). ... for use in MRI. Today, the product ... in CNS, head, neck and body. MAGNEVIST ...
... is a nonionic, iodinated, low-osmolar radiological ... in the U.S. in 1995, ten ... ULTRAVIST today is used in ... a positive clinical experience in more ...
The Pinn-ACL Guide can be used to create tibial tunnels of known lengths with a variable angle adjustment of 35 to 60 degrees with the use of a,graduated pin-sleeve....
Forceps with round handle, straight...
Medicine Products: